Arcadia Biosciences (RKDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 1 year price objectives for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 361.6% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.

Arcadia Biosciences' stock was trading at $0.2710 at the beginning of the year. Since then, RKDA stock has increased by 1,099.2% and is now trading at $3.2499.
View the best growth stocks for 2023 here.

Arcadia Biosciences saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 600 shares, a decrease of 87.2% from the August 15th total of 4,700 shares. Based on an average trading volume of 38,900 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the company's stock are short sold.
View Arcadia Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RKDA earnings forecast.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its earnings results on Thursday, August, 10th. The basic materials company reported ($2.64) earnings per share for the quarter, beating analysts' consensus estimates of ($4.92) by $2.28. The basic materials company earned $1.39 million during the quarter, compared to the consensus estimate of $1.43 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 69.76% and a negative net margin of 271.33%.

Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Arcadia Biosciences updated its second quarter 2023 earnings guidance on Thursday, July, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 million-$1.50 million, compared to the consensus revenue estimate of $1.82 million.

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RKDA stock can currently be purchased for approximately $3.25.

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.61 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($21.36) on an earnings per share basis.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.